Medgenics Announces Registration of Shares to Be Issued upon Exercises of Warrants Listed on NYSE MKT
23 July 2012 - 10:30PM
Business Wire
Medgenics, Inc. (NYSE MKT: MDGN and MDGN.WS and AIM: MEDG and
MEDU), the developer of BiopumpTM, a novel technology for the
sustained production and delivery of therapeutic proteins in
patients using their own tissue, today announced the availability
of a current prospectus following the effectiveness of its
registration in the United States of common stock issuable upon the
exercise of outstanding warrants to purchase 2,829,000 shares of
common stock.
The warrants were originally issued in the Company’s initial
public offering in the United States in April 2011 and are listed
on the NYSE MKT (formerly the NYSE Amex) under the symbol
“MDGN.WS.” Each warrant is exercisable for one share of the
Company’s common stock, listed on the NYSE MKT under the symbol
“MDGN.”
The shares of common stock issuable upon exercise of the
warrants are being offered by the Company pursuant to a
registration statement previously filed and declared effective by
the Securities and Exchange Commission on July 20, 2012. Electronic
copies of the prospectus may be obtained at the Securities and
Exchange Commission’s website at http://www.sec.gov. Copies of the
prospectus may also be obtained from Corporate Stock Transfer,
Inc., as warrant agent, by contacting it at 3200 Cherry Creek Drive
South, Suite 4300, Denver, Colorado 80209, or (303) 282-4800.
In order to exercise a warrant, the holder must deliver to
Corporate Stock Transfer, Inc., 3200 Cherry Creek Drive South,
Suite 4300, Denver, Colorado 80209:
- the original warrant certificate
- a completed and executed exercise form
located on the reverse side of the warrant certificate and
- full payment of the exercise price, by
certified check payable to “Medgenics Warrant Exercise Account” or
by wire transfer of immediately available funds.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Medgenics
Medgenics is developing Biopump™, a proprietary tissue-based
platform technology for the sustained production and delivery of
therapeutic proteins using the patient's own skin biopsy for the
treatment of a range of chronic diseases including anemia,
hepatitis, and hemophilia, among others.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024